Eleven postmenopausal patients with advanced breast cancer were assessed for their reponse and endocrine changes to low-dose aminoglutethimide (250 mg twice a day) therapy without steroid administration. In 7 cases an objective response was registered; 1 patient had a stabilization of the disease lasting for 9 months. Significant falls in plasma estrogen and rises in plasma androgen levels were observed, while those of Cortisol and ACTH remained essentially unchanged. No serious side effects occurred.
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً